Citius Pharmaceuticals DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

About Contact Details

Our first product, Suprenza®, a novel formulation of a leading obesity drug, was recently approved by the FDA. We have licensed the product to Akrimax, LLC, for sales and marketing of the product. We intend to continue our innovation to further improve our formulation and are conducting clinical studies to expand the market opportunity for Suprenza. We also have a second product, addressing a common gastrointestinal condition...

Our first product, Suprenza®, a novel formulation of a leading obesity drug, was recently approved by the FDA. We have licensed the product to Akrimax, LLC, for sales and marketing of the product. We intend to continue our innovation to further improve our formulation and are conducting clinical studies to expand the market opportunity for Suprenza. We also have a second product, addressing a common gastrointestinal condition, entering Phase 2 studies. We actively seek additional product ideas at all stages of development to strengthen our pipeline.